Synta Pharmaceuticals Corporation (SNTA)

Oncology Corporate Profile

Stock Performance

15.5000
0.4500

HQ Location

45 Hartwell Avenue
Lexington, MA 02421

Company Description

Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has an extensive group of small molecule drug candidates with unique chemical structures and distinct methods of action. STA-9090 is in Phase I clinical trial for solid tumors and Phase I/II clinical trial for hematologic cancers. STA-9584 is a vascular disrupting agent and is in preclinical development for cancer. Synta was incorporated in 2000.

Website: http://www.syntapharma.com

This company does not have any commercial products

This company does not have any pipeline products

Pipeline image

Source


http://www.syntapharma.com

Recent News Headlines

With $163M Deal, Tarveda Revives Synta Pharma’s Cancer Drug Work

9/19/2016 11:31 am

(Xconomy Boston) Sept 19, 2016 - The wheeling and dealing for Tarveda Therapeutics (formerly Blend Therapeutics) continued this morning for the Watertown, MA, company, which has cut a deal with Madrigal Pharmaceuticals—the firm that recently merged with now-defunct Synta Pharmaceuticals—to add another potential cancer drug to the mix.

Phase III Study of Genentech’s Alecensa® (Alectinib) Showed Superior Efficacy Versus Crizotinib in Japanese People With a Specific Type of Lung Cancer

5/19/2016 12:02 pm

(Genentech) May 18, 2016 - First investigational head-to-head study of Alecensa versus crizotinib in people with advanced ALK-positive non-small cell lung cancer (NSCLC).

Omega-3 Fatty Acids May Lower Breast Cancer Risk In Postmenopausal Obese Women

2/24/2016 11:05 am

(Penn State News) Feb 24, 2016 - Omega-3 fatty acids may lower the risk of breast cancer in postmenopausal obese women, according to researchers.

Drug Industry Launches Ad Campaign Aimed at Lawmakers

2/8/2016 12:01 pm

(Wall Street Journal) Feb 7, 2016 - The pharmaceutical industry, under fire this election season for rising drug prices, is ramping up a new advertising campaign designed to improve its reputation with lawmakers as it lobbies against any effort to rein in prescription costs.

Bone Loss Associated With Leukemia Therapy Occurs Sooner Than Previously Thought

2/5/2016 11:03 am

(CHLA) Feb 4, 2016 - Investigators at Children's Hospital Los Angeles have found that significant bone loss – a side effect of chemotherapy for acute lymphoblastic leukemia (ALL) – occurs during the first month of treatment, far earlier than previously assumed.

Synta Halts Study Of Lung Cancer Treatment, Stock Plummets

10/21/2015 10:34 am

(Reuters) Oct 20, 2015 - Synta Pharmaceuticals Corp has decided to end a late-stage trial of its lung cancer treatment after an independent review said it proved ineffective, nearly halving its stock in extended trading on Tuesday.

Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer

10/21/2015 06:58 am

(StreetInsider) Oct 20, 2015 - Synta Pharmaceuticals Corp. today announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma.

Synta Pharmaceuticals Announces Formation of Expert Oncology Panel

10/8/2015 12:47 pm

(CNBC) Oct 8, 2015 - Synta Pharmaceuticals Corp. today announced the formation of an Expert Oncology Panel to provide guidance on research and development strategies for the Company’s portfolio of novel oncology therapies.

Merck, Pfizer Team with Dako for Avelumab Companion Diagnostic

9/25/2015 11:05 am

(PharmaTimes [UK]) Sept 25, 2015 - Merck KGaA and Pfizer have drafted in Danish group Dako to work on a companion diagnostic for their investigational anti-PD-L1 antibody avelumab.

Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma

9/25/2015 11:05 am

(StreetInsider) Sept 25, 2015 - Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.

Bristol-Myers Squibb and Moffitt Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program

9/25/2015 11:05 am

(MarketWatch) Sept 25, 2015 - Bristol-Myers Squibb Company and Moffitt Cancer Center today announced that they have entered into a collaboration agreement as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.

CHMP Grants Accelerated Assessment for Daratumumab for Double Refractory Multiple Myeloma

9/25/2015 11:05 am

(NASDAQ) Sept 25, 2015 - Genmab A/S announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment to the Marketing Authorization Application (MAA) for daratumumab.

Summary of Opinion (post authorisation): Opdivo (nivolumab)

9/25/2015 11:05 am

(EMA) Sept 24, 2015 - On 24 September 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Opdivo.

MD Anderson Study Identifies Leukemia Tumor Suppressor

9/25/2015 11:04 am

(MD Anderson) Sept 24, 2015 - A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals.

Childhood Brain Tumors Affect Working Memory of Adult Survivors, Georgia State/Emory Study Finds

9/25/2015 11:04 am

(Georgia State University) Sept 24, 2015 - Adult survivors of childhood brain tumors have lower working memory performance compared to healthy adults, according to researchers at Georgia State University and Emory University.

Fungi May Lead to Cheaper Cancer Treatment: U of G Study

9/25/2015 11:04 am

(University of Guelph [Canada]) Sept 24, 2015 - Cheaper anti-cancer drugs for humans might ultimately stem from a new study by University of Guelph scientists into a kind of microbial "bandage" that protects yew trees from disease-causing fungi.

Novartis CEO Talks about Drug Costs, Paying Doctors and 'Doing the Right Thing'

9/25/2015 11:04 am

(Washington Post) Sept 24, 2015 - As stories of jacked-up drug costs make news, and discussions of health-care reform pepper the campaign trail, Novartis CEO Joseph Jimenez sat down with The Washington Post to talk about how he views his responsibility as leader of one of the world's largest pharmaceutical companies.

Are Medicare Prescription Benefits Too Stingy?

9/25/2015 11:04 am

(Forbes) Sept 23, 2015 - According to a recent study, out-of-pocket chemotherapy costs are often two, three, even four times higher for Medicare recipients than for people with private insurance.

New Combos, Targets Offer Optimism for Myeloma

9/25/2015 11:03 am

(MedPage Today) Sept 24, 2015 - Novel therapeutic targets in multiple myeloma and cellular immune therapies hold promise for extending patient outcomes beyond the boundaries established by recent additions to treatment options, a myeloma researcher said here.

'Remote Control' of Immune Cells Opens Door to Safer, More Precise Cancer Therapies

9/25/2015 11:03 am

(UCSF) Sept 24, 2015 - UC San Francisco researchers have engineered a molecular "on switch" that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer.

Promising Drugs Turn Immune System on Cancer

9/25/2015 11:03 am

(Cancer Research UK) Sept 24, 2015 - Cancer Research UK scientists have shown that a class of experimental drug treatments already in clinical trials could also help the body's immune system to fight cancer, according to a study published today (Thursday) in the journal Cell.

Cancer Therapies' Impact On Heart, Kidneys Explored

9/25/2015 11:03 am

(VICC) Sept 24, 2015 - Vanderbilt is embarking on a multi-disciplinary approach to understand how promising cancer treatments, specifically certain kinase inhibitors, affect the heart and kidneys.

Team to Explore Using Nanoparticles to Fight Cancer

9/25/2015 11:03 am

(VICC) Sept 24, 2015 - Three Vanderbilt researchers have received a federal grant to study the use of nanoparticles to deliver potential therapies for breast cancer that has spread to the bone.

Synta Announces Ganetespib Program Updates

6/2/2015 04:56 pm

(Synta) June 2, 2015 - Synta Pharmaceuticals Corp. today announced updates to its clinical program for Ganetespib, a next-generation inhibitor of the chaperone protein Hsp90.

A Surge in Interest in Synta's Cancer Drug Ahead of Key Science Data

4/17/2015 12:27 pm

(Boston Business Journal/BioFlash blog) Apr 16, 2015 - With the first trial results from a Phase 3 trial of the lead cancer drug at Synta Pharmaceuticals still several months away, the firm’s shares are on the rise on the promise of data planned for a conference next week.

Lexington-based Synta to Cut 20 Percent of Workforce and Consolidate Lab Space

2/6/2015 12:23 pm

(Boston Business Journal) Feb 6, 2015 - Lexington biotech Synta Pharmaceuticals has announced plans to eliminate 20 percent of its workforce as it slims down to focus on two potential cancer drugs.

Synta Announces Presentation of Results From an Investigator-Sponsored Phase 1 Trial of Ganetespib in HER2+ Metastatic Breast Cancer at the 2014 San Antonio Breast Cancer Symposium

12/12/2014 02:43 pm

(Synta) Dec 12, 2014 - Synta Pharmaceuticals Corp. today announced presentation of preliminary results from an investigator-sponsored phase 1 trial, designed to evaluate ganetespib in combination with paclitaxel and trastuzumab in women with HER2+ metastatic breast cancer (MBC) refractory to other HER2 inhibitors.

Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors

12/10/2014 02:05 pm

(Bristol-Myers Squibb) Dec 10, 2014 - Ono Pharmaceutical Co.,Ltd., Bristol-Myers Squibb Company and Kyowa Hakko Kirin Co., Ltd. announced today the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody.

Long Radiation Treatments Faulted in Many Breast Cancer Cases

12/10/2014 02:01 pm

(New York Times) Dec 10, 2014 - Two-thirds of women who have lumpectomies for breast cancer are getting radiation treatment that lasts nearly twice as long as necessary, a new study reports.

Triple-negative Breast Cancer Patients Should Undergo Genetic Screening

12/2/2014 11:04 am

(Mayo Clinic) Dec 2, 2014 - Most patients with triple-negative breast cancer should undergo genetic testing for mutations in known breast cancer predisposition genes, including BRCA1 and BRCA2, a Mayo Clinic-led study has found.

Synta Announces FDA's Oncologic Drugs Advisory Committee to Discuss Pediatric Uses for Ganetespib

11/5/2014 12:30 pm

(Synta) Nov 5, 2014 - Synta Pharmaceuticals Corp. today announced that the Company has been invited by the U.S. Food and Drug Administration (FDA) to participate in a meeting of the Oncologic Drugs Advisory Committee’s (ODAC) Pediatric Subcommittee on December 11, 2014.

Synta Announces Initiation of I-SPY 2 TRIAL of Ganetespib in Breast Cancer

10/29/2014 11:58 am

(Yahoo! Finance) Oct 29, 2014 - Synta Pharmaceuticals Corp. today announced the initiation of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) arm evaluating ganetespib, the Company’s Hsp90 inhibitor, as a neoadjuvant therapy for patients with breast cancer.

Synta Announces Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Study for Patients with AML and High-Risk MDS

7/22/2014 11:56 am

(MarketWatch) July 21, 2014 - Synta Pharmaceuticals Corp. today announced the advancement of ganetespib into the Phase 3 extension of the AML LI-1 (less intensive) trial.

Synta Announces Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Study for Patients with AML and High-Risk MDS

7/22/2014 06:05 am

(MarketWatch) July 21, 2014 - Synta Pharmaceuticals Corp. today announced the advancement of ganetespib into the Phase 3 extension of the AML LI-1 (less intensive) trial.

ASCO: Time to Change Lung Ca Surrogate Endpoint?

6/1/2014 01:05 pm

(MedPage Today) June 1, 2014 - An FDA meta-analysis supported response rate as a surrogate endpoint in metastatic non-small cell lung cancer, but others said it’s time to look beyond conventional measures.

Synta Announces Results From Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC

5/8/2014 12:16 pm

(Synta) May 8, 2014 - Synta Pharmaceuticals Corp. today announced final results from the GALAXY-1 trial, a global, randomized, multi-center study designed to identify the patients with advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology most likely to benefit from second-line treatment with the Company’s lead drug candidate, the Hsp90 inhibitor ganetespib, in combination with docetaxel versus docetaxel alone.

Synta Announces Results From Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC

5/8/2014 07:01 am

(Synta) May 8, 2014 - Synta Pharmaceuticals Corp. today announced final results from the GALAXY-1 trial, a global, randomized, multi-center study designed to identify the patients with advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology most likely to benefit from second-line treatment with the Company’s lead drug candidate, the Hsp90 inhibitor ganetespib, in combination with docetaxel versus docetaxel alone.